Backabrdn Life Sciences Investors Overview

abrdn Life Sciences Investors Cost of Revenue

Cost of Revenue analysis for HQL.

Quarterly Cost of Revenue

$3.12M
23.35% YoY

As of Mar 31, 2026

Annual Cost of Revenue (TTM)

$3.12M
59.92% YoY

Trailing 12 months ending Mar 31, 2026

Average Cost of Revenue (Comparison Companies)

Cost of Revenue History

Cost of Revenue Comparison

Annual Cost of Revenue Growth Rate (%)

Annual Cost of Revenue Growth (Absolute)